InvestSMART

Nanosonics Limited (ASX: NAN) - Announcements

Current share price for NAN : $2.760 0.01 (0.36%)+

ASX company news and announcements for Nanosonics Limited (NAN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nanosonics Limited (NAN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nanosonics Limited (NAN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nanosonics Limited (NAN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$825 Business update and App 4C Quarterly cashflow statement 29 Jul 2010 11:35AM $0.580 $2.760 risen by 375.86%
$825 Update on production and FDA application 29 Jun 2010 10:22AM $0.535 $2.760 risen by 415.89%
$825 App 4C Statement of Cash Flows and comments 29 Apr 2010 2:47PM $0.560 $2.760 risen by 392.86%
$825 Commercial Update 14 Apr 2010 12:54PM $0.610 $2.760 risen by 352.46%
$825 Commercial Update 26 Feb 2010 11:19AM $0.520 $2.760 risen by 430.77%
$825 Appendix 4D Half Year Results to December 2009 11 Feb 2010 4:00PM $0.565 $2.760 risen by 388.50%
$825 Consolidated Statement of Cashflows for half-year to Dec 09 1 Feb 2010 9:45AM $0.490 $2.760 risen by 463.27%
$825 Company Update 22 Dec 2009 4:31PM $0.570 $2.760 risen by 384.21%
$825 A$12 Million underwritten placement completed 8 Dec 2009 10:05AM $0.575 $2.760 risen by 380%
$825 $12million underwritten placement plus share purchase plan 7 Dec 2009 10:46AM $0.625 $2.760 risen by 341.60%
$825 Trading Halt 7 Dec 2009 10:03AM $0.625 $2.760 risen by 341.60%
$825 Response to ASX Price Query 19 Nov 2009 4:46PM $0.620 $2.760 risen by 345.16%
$825 Business Update and App4C Cash Flow Statement 30 Oct 2009 1:02PM $0.590 $2.760 risen by 367.80%
$825 Response to Price Query 22 Sep 2009 10:16AM $0.500 $2.760 risen by 452%
$825 2009 Results and 4E Statement 21 Aug 2009 9:15AM n/a $2.760 n/a
$825 4C Statement for quarter and year ended 30 June 2009 31 Jul 2009 3:20PM $0.470 $2.760 risen by 487.23%
$825 510(k) application to FDA and Trophon tender successes 13 May 2009 9:55AM $0.360 $2.760 risen by 666.67%
$825 Consolidated Statement of Cash Flows to 31 March 2009 30 Apr 2009 3:25PM $0.310 $2.760 risen by 790.32%
$825 First Sales of Trophon EPR 30 Mar 2009 10:04AM $0.310 $2.760 risen by 790.32%
$825 Appendix 4D - 2009 Interim Report 17 Feb 2009 9:23AM $0.300 $2.760 risen by 820%
$825 TGA Approves Trophon EPR. Sales on track for Feb 2009 3 Feb 2009 12:42PM $0.210 $2.760 risen by 1,214.29%
$825 Appendix 4C Quarterly Cash Flow Report 30 Jan 2009 1:58PM $0.210 $2.760 risen by 1,214.29%
$825 Key Commercial Milestones Achieved 12 Dec 2008 10:33AM $0.195 $2.760 risen by 1,315.38%
$825 Appointment of Distributors and Statement of Cashflows 16 Oct 2008 8:29AM $0.180 $2.760 risen by 1,433.33%
$825 Approval to Market in Canada 9 Sep 2008 2:00PM $0.240 $2.760 risen by 1,050%

776 - 800 of 814 results

Page 32 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.